National Comprehensive Cancer Network



About NCCN

NCCN Guidelines™ and NCCN Compendium™ Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) and NCCN Drugs & Biologics Compendium (NCCN Compendium™) for Multiple Myeloma.  These NCCN Guidelines™ are currently available as Version 1.2011.

In the updated guidelines, serum-free light chain assay is now included as a part of the initial diagnostic work-up. Previously, it was included under tests that may be useful under some circumstances. Also, 1q21 amplification has been added to the FISH panel under initial diagnostic work-up.

Bortezomib/cyclophosphamide/dexamethasone has been added to the list of options under primary induction therapy for transplant candidates. Bortezomib/dexamethasone and Melphalan/prednisone/lenalidomide have been added to the list of options under primary induction therapy for non-transplant candidates.

Additionally, the following representative regimens that combine standard agents with novel agents have been added to the list of options under salvage therapy: cyclophosphamide/bortezomib/dexamethasone and cyclophosphamide/lenalidomide/dexamethasone.

For Systemic Light Chain Amyloidosis, two new regimens have been added to primary treatment options.  These are bortezomib/dexamethasone and cyclophosphamide/thalidomide/dexamethasone (CTD) regimens.

All of these additions are designated as category 2A.

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) and NCCN Drugs & Biologics Compendium (NCCN Compendium™) for Small Cell Lung Cancer.  These NCCN Guidelines™ are currently available as Version 1.2011.

The Principles of Radiation Therapy section has been updated. The TNM staging system for Small Cell Lung Cancer has been modified for consistency with the 7th edition of the American Joint Committee on Cancer (AJCC) Staging Manual.

For the complete updated versions of the NCCN Guidelines™ and the NCCN Compendium™ please visit NCCN.org.

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved